Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo

BACKGROUND: Tamoxifen (TAM) is a cell type-specific anti-estrogen and is applied to improve the survival of patients with estrogen receptor positive (ER +) breast cancer. However, long-term TAM use can induce serious drug resistance, leading to breast cancer recurrence and death in patients. Further...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Hong-Yan, Han, Hong-Wei, Wang, Yin-Song, He, De-Liu, Sun, Wen-Xue, Feng, Lu, Wen, Zhong-Ling, Yang, Min-Kai, Lu, Gui-Hua, Wang, Xiao-Ming, Qi, Jin-Liang, Yang, Yong-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063777/
https://www.ncbi.nlm.nih.gov/pubmed/32175001
http://dx.doi.org/10.1186/s13020-020-00305-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063777/
https://www.ncbi.nlm.nih.gov/pubmed/32175001
http://dx.doi.org/10.1186/s13020-020-00305-1

Ejemplares similares